Edition:
United Kingdom

Merck's Keytruda Approved In China For First-Line Treatment For A Form Of Lung Cancer


Monday, 1 Apr 2019 

April 1 (Reuters) - Merck & Co Inc ::MERCK’S KEYTRUDA® (PEMBROLIZUMAB) APPROVED IN CHINA FOR FIRST-LINE TREATMENT OF METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN COMBINATION WITH CHEMOTHERAPY.MERCK - CONTINUED APPROVAL MAY BE CONTINGENT UPON VERIFICATION AND DESCRIPTION OF CLINICAL BENEFIT IN CHINESE PATIENTS IN A CONFIRMATORY TRIAL.